DrugPatentWatch Database Preview
NASONEX Drug Profile
Which patents cover Nasonex, and when can generic versions of Nasonex launch?
Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty-six patent family members in thirty-three countries.
The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for NASONEX
| International Patents: | 46 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 58 |
| Clinical Trials: | 45 |
| Patent Applications: | 4,164 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NASONEX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASONEX |
| DailyMed Link: | NASONEX at DailyMed |
Pharmacology for NASONEX
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for NASONEX
Synonyms for NASONEX
| (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
| (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
| (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
| [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
| 04201GDN4R |
| 11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
| 2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester |
| 83919-23-7 |
| 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| 9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) |
| 919M237 |
| A840685 |
| AB2000407 |
| AC-941 |
| AC1L9AZS |
| AK163902 |
| AKOS015994732 |
| AN-15438 |
| Asmanex |
| Asmanex HFA |
| Asmanex Twisthaler |
| BC228151 |
| BDBM50148733 |
| BPBio1_000424 |
| BRD-K60640630-001-03-7 |
| BRN 4340538 |
| BSPBio_000384 |
| C07817 |
| C27H30Cl2O6 |
| CAS-83919-23-7 |
| CCG-220572 |
| CHEBI:47564 |
| CHEMBL1161 |
| CS-2389 |
| D00690 |
| Danitin |
| DR003147 |
| DSSTox_CID_3333 |
| DSSTox_GSID_23333 |
| DSSTox_RID_76981 |
| DTXSID4023333 |
| Ecural |
| Elocon |
| Elocone |
| Elomet |
| Flumeta |
| HMS1569D06 |
| HMS2096D06 |
| HMS2235I14 |
| HY-13693 |
| KS-00000SPL |
| KS-1275 |
| LAS 41002 |
| M2354 |
| MLS002153879 |
| MolPort-003-849-257 |
| Mometasone 17-(2-furoate) |
| mometasone 17-furoate |
| mometasone furancarboxylate |
| mometasone furoate |
| Mometasone furoate (JAN/USP) |
| Mometasone furoate [USAN:USP:JAN] |
| Mometasone furoate hydrate |
| Mometasone Furoate Impurity G |
| MOMETASONE FUROATE MONOHYDRATE |
| Mometasone furoate, >=98% (HPLC) |
| Mometasone furoate, European Pharmacopoeia (EP) Reference Standard |
| Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
| Mometasone furoate, United States Pharmacopeia (USP) Reference Standard |
| Monovo |
| NCGC00016950-01 |
| NCGC00179578-01 |
| NCGC00179578-03 |
| NCGC00179578-04 |
| Nosorex |
| NSC-746171 |
| NSC746171 |
| Ovixan |
| PL071566 |
| Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- |
| Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)- |
| Prestwick_924 |
| Prestwick0_000572 |
| Prestwick1_000572 |
| Prestwick2_000572 |
| Prestwick3_000572 |
| Q-101380 |
| Rimelon |
| s1987 |
| Sch 32088 |
| Sch-32088 |
| SCHEMBL4568 |
| Sinuva |
| SMR001233233 |
| SPBio_002603 |
| SR-01000841209 |
| SR-01000841209-2 |
| ST24048112 |
| TL8005500 |
| Tox21_110705 |
| Tox21_110705_1 |
| UNII-04201GDN4R |
| WOFMFGQZHJDGCX-ZULDAHANSA-N |
| ZINC3938677 |
US Patents and Regulatory Information for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NASONEX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 50 mcg/ Spray | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for NASONEX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Estonia | 02962 | ➤ Try a Free Trial |
| South Africa | 9107148 | ➤ Try a Free Trial |
| Australia | 663471 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for NASONEX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 875032 | Germany | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
| 5/1998 | Austria | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT |
| C/GB97/064 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
